## Human CDH17/Cadherin 17 Domain 4 Protein, Ultra Low Endotoxin

therapeutic approach.






| Description             |   |
|-------------------------|---|
| Source                  | Recombinant Human CDH17/Cadherin 17 Domain 4 Protein is expressed from HEK293 with mFc (IgG2a) tag at the C-terminus.   |
|                         | It contains Pro341-Phe449.  |
| Accession               | Q12864  |
| Molecular<br>Weight     | The protein has a predicted MW of 38.78 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.   |
| Endotoxin               | Less than 0.001 EU per μg by the LAL method.  |
| Purity                  | > 95% as determined by Bis-Tris PAGE  |
| Formulation and Storage |   |
| Formulation             | Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.   |
| Reconstitution          | Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.   |
| Storage                 | -20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.   |
| Background              |   |
|                         | Liver-intestine cadherin (CDH17) has been known to function as a tumor stimulator and diagnostic marker for almost two decades. In vivo studies showed CDH17 knockout resulted in apoptotic PC tumor death through activating caspase-3 activity. Taken together, CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways and CDH17 could be targeted to develop an anti-PC |

## **Assay Data**

## **Bis-Tris PAGE**



Human CDH17 Domain 4 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.